“Bone Grafts and Substitutes Market Report is set to have rapid growth due to the factors, such as High awareness regarding the commercially available products, higher healthcare expenditure, and availability of advanced healthcare infrastructure at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Bone Grafts and Substitutes Market Forecast 2019-2029: By Material Type (Natural, Synthetic), By Application Type (Spinal Fusion, Craniomaxillofacial, Long Bone), By Region, And Segment Forecasts

Bone Grafts and substitutes are broadly utilized in orthopedic medical procedures for various applications. Rising instances of orthopedic issues due to weakened bones is forecasted to have higher demand in the coming future, projected from 2019-2029.

According to the United Nations Department of Economic and Social Affairs, Population Division, the number of people over the age of 60 was 841 million in 2013 and is expected to reach 2 billion in 2050. Therefore, the number of orthopedic surgeries it should increase with an increasing geriatric population that is more prone to orthopedic disorders. Therefore, it is expected that the market will see significant demand during the forecast period.

However, the risk of disease transmission and the immune response are the main factors that hinder market growth. Furthermore, the high cost of advanced products and the rigorous regulatory process involved further limit market development. Furthermore, the ethical issues associated with bone harvesting limit market growth in some regions.

The market is divided into global bone graft segments, replacing market reports based on material, application, and region.

Major applications include craniofacial, dentistry, feet and ankles, joint reconstruction, long bones, and spinal fixation. Improved reimbursement scope and the presence of a large elderly patient population are some of the factors that support market growth.

Leading companies featured in the report include: DePuy Synthes; Medtronic PLC; Nuvasive, Inc.; Orthofix Holdings, Inc.; Wright Medical Group N.V.; AlloSource, Inc.; and Stryker Corp.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever